Levothyroxine Bioequivalence Standards Will Remain, FDA Tells Workshop
Executive Summary
FDA will not alter its bioequivalence standards for levothyroxine products despite concerns from three thyroid and endocrine medical societies, the agency said at a May 23 public meeting held in Washington, D.C
You may also be interested in...
Tighter Levothyroxine Standards Are Only First Step To Higher Quality – Cmte.
Tightening levothyroxine potency standards will not address underlying concerns about the quality of the manufacturing process for such products, members of the Endocrinologic & Metabolic Drugs and Pharmaceutical Science Advisory Committees said
Tighter Levothyroxine Standards Are Only First Step To Higher Quality – Cmte.
Tightening levothyroxine potency standards will not address underlying concerns about the quality of the manufacturing process for such products, members of the Endocrinologic & Metabolic Drugs and Pharmaceutical Science Advisory Committees said
Levothyroxine BE Studies In Athyreotic Patients Would Be “Unrealistic” – FDA
Levothyroxine bioequivalence studies in patients with no thyroid activity that also measure thyroid stimulating hormone would be "unrealistic," FDA said during the meeting of the Advisory Committee for Pharmaceutical Science March 13